{"nctId":"NCT01685073","briefTitle":"The Role of Sleep in the Treatment of Cannabis Use Disorders","startDateStruct":{"date":"2012-09"},"conditions":["Drug Addiction"],"count":127,"armGroups":[{"label":"Zolpidem","type":"EXPERIMENTAL","interventionNames":["Drug: Zolpidem extended-release","Behavioral: MET/CBT"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Behavioral: MET/CBT"]}],"interventions":[{"name":"Zolpidem extended-release","otherNames":["Ambien CR"]},{"name":"MET/CBT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18-55 years.\n2. Recent problematic use of cannabis\n3. Cannabis use impacts sleep\n\nExclusion Criteria:\n\n1. Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric disorder\n2. Moderate sleep apnea or periodic limb movement disorder\n3. Pregnant, breast feeding, or planning to become pregnant within the next 3 months\n4. Current condition associated with severe cognitive/social impairment\n5. Allergy to any ingredient in extended-release zolpidem or prior adverse reaction to zolpidem\n6. Current use of drugs that affect metabolism via cytochrome P450 or current illness resulting in severe hepatic impairment\n7. Current use of hypnotic medications","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed","description":"Percentage of time asleep while in bed is measured using ambulatory polysomnography (PSG) equipment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":"16"},{"groupId":"OG001","value":"74","spread":"19"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Cannabis Abstinence as Assessed by Urine Cannabis Testing","description":"Qualitative urine cannabis testing outcomes of study participants; missing drop-outs presumed positive; Negative = THCCOOH \\<50ng/mL via EIA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":62},"commonTop":["Cold symptoms","nausea","emesis","Headache","toothache"]}}}